The Indian pharmaceutical industry has demonstrated incredible tenacity and dedication in the face of the pandemic's devastation. Indian medications are popular all throughout the world, but particularly in the US because of their excellent quality and reasonable rates. India had a substantial growth in pharmaceutical exports relative to its overall exports during the pandemic period. This article aims to examine India's pharmaceutical product exports during and after the COVID-19 pandemic. To fulfil the study ,it used the literature from sources such as, Aaheli Ahmed et al.'s 2020 study, "The recent Coronavirus (COVID-19)Pandemic: A Review of issues for Indian Pharmaceuticals Exports," which highlighted potential trade opportunities for India's pharmaceutical sector in light of recent export policy interventions, RBI Bulletin July 15, 2021 (Drivers of Indian Pharmaceutical Exports), the Department of Pharmaceuticals' Annual Report, Government of India, 2021-22, the ITC Trade Map Data, etc., were among the other publications reviewed for this study. To achieve the objectives, the study utilized some indices. The BRCA index has been evaluated to analyze the export pattern of India with world at the disaggregate level (HS-6 digits) for Pharma sector. The RCA of a particular commodity is measured by the share of that commodity in the country's total exports relative to the country's share in the total world exports. The paper`s findings highlight that India’s RCA index is above 1 for API’s, Bulk Drugs and Formulations for the past many years. Whereas the value of this index is below 1 for other pharmaceuticals category over the period.